During a press conference at the SABCS 2013, Dr Dennis Slamon presents data from the recent BETH study.
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumour size and whether or not disease has spread to the lymph nodes, according to results from the study.